Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET

Company Participants

Kyle Gano - Chief Executive Officer
Matt Abernethy - Chief Financial Officer
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Todd Tushla - Vice President of Investor Relations

Conference Call Participants

Chris Shibutani - Goldman Sachs
Paul Matteis - Stifel
David Ansellem - Piper Sandler
Phoebe Tan - Jefferies
Tazeen Ahmad - Bank of America Securities
Jay Olson - Oppenheimer
Ash Verma - UBS
Philip Nadeau - TD Cowen
Anupam Rama - J.P. Morgan
Evan Seigerman - BMO Capital Markets
Cory Kasimov - Evercore ISI
Carter Gould - Barclays
Mohit Bansal - Wells Fargo
Marc Goodman - Leerink Partners
Myles Minter - William Blair
Michael Riad - Morgan Stanley
Laura Chico - Wedbush Securities
Yatin Suneja - Guggenheim Securities
Uy Ear - Mizuho Securities
Ami Fadia - Needham

Operator

Good day, everyone and welcome to Neurocrine Biosciences’ reports Third Quarter Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer period. [Operator Instructions] Please note that this call will be recorded and I will be standing by should you need any assistance.

It is now my pleasure to turn today’s call over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

Todd Tushla

Thank you, and happy Halloween eve. Welcome to Neurocrine Biosciences’ third quarter 2024 earnings call. With me are Kyle Gano, our Chief Executive Officer; and Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; and Eiry Roberts, Chief Medical Officer.

Note that today, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings.

With that, for the first time, I hand it over to Kyle.

Kyle Gano

Thank you, Todd. Before we dive in, I'd like to acknowledge that this is my first earnings call as Neurocrine’s CEO. I'm excited to share my enthusiasm for our future, so my opening remarks may run a bit longer than usual.

First, I want to express my deep gratitude to our Board of Directors for their confidence in my leadership as we embark on this next chapter of growth. Thanks to the exceptional guidance of our past CEOs, Gary Lyons and Kevin Gorman, Neurocrine is in a strong position to become a true leader in neuroscience. I extend my heartfelt thanks to both Gary and Kevin for their invaluable contributions to the company's success.